We are live on ! Find out more
ICCM icon

IceCure Medical

18 hedge funds and large institutions have $319K invested in IceCure Medical in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

13% more funds holding

Funds holding: 1618 (+2)

7% more capital invested

Capital invested by funds: $298K → $319K (+$20.5K)

0.34% more ownership

Funds ownership: 0.43%0.76% (+0.34%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
2
Reduced
2
Closed
3
Calls
Puts
Net Calls
Net Calls Change

ICCM Hedge Fund Activity: Q4 2025 in Review

18 of the 8,276 institutional investors tracked by Wall St. Rank reported a position in IceCure Medical (ICCM) for Q4 2025, worth a combined $319K — up 6.9% from $298K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ICCM positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $82K. The largest seller was Citadel Advisors, exiting entirely with an estimated $37.9K sold.

  • 18 institutional investors held IceCure Medical (ICCM) as of Q4 2025, up from 16 in Q3 2025.
  • Funds reported $319K of IceCure Medical stock for Q4 2025, up 6.9% quarter-over-quarter.
  • 5 funds opened new IceCure Medical positions in Q4 2025 and 3 closed out, a net change of +2 holders.
  • The largest IceCure Medical buyer in Q4 2025 was Jane Street, an estimated $82K added.
  • The largest IceCure Medical seller in Q4 2025 was Citadel Advisors, an estimated $37.9K sold.

Based on aggregated 13F filings for Q4 2025.